Molecular Partners AG (0QXX.L)
0QXX.L Stock Price Chart
Explore Molecular Partners AG interactive price chart. Choose custom timeframes to analyze 0QXX.L price movements and trends.
0QXX.L Company Profile
Discover essential business fundamentals and corporate details for Molecular Partners AG (0QXX.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
5 Nov 2014
Employees
158.00
CEO
Patrick Amstutz
Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
0QXX.L Financial Timeline
Browse a chronological timeline of Molecular Partners AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Mar 2026
Upcoming earnings on 25 Aug 2025
Earnings released on 15 May 2025
EPS came in at -CHF 0.45 falling short of the estimated -CHF 0.36 by -25.00%.
Earnings released on 6 Mar 2025
EPS came in at -CHF 0.30 surpassing the estimated -CHF 0.39 by +21.87%.
Earnings released on 1 Nov 2024
EPS came in at -CHF 0.49 surpassing the estimated -CHF 0.54 by +8.48%, while revenue for the quarter reached CHF 681.00K, beating expectations by +94.57%.
Earnings released on 27 Aug 2024
EPS came in at -CHF 0.45, while revenue for the quarter reached CHF 1.55M, beating expectations by +93.88%.
Earnings released on 17 Apr 2024
EPS came in at -CHF 0.34, while revenue for the quarter reached CHF 2.74M, beating expectations by +1.41%.
Earnings released on 15 Mar 2024
EPS came in at -CHF 0.60, while revenue for the quarter reached CHF 1.03M, beating expectations by +158.00%.
Earnings released on 30 Sept 2023
EPS came in at -CHF 0.35, while revenue for the quarter reached CHF 2.54M, beating expectations by +81.50%.
Earnings released on 30 Jun 2023
EPS came in at -CHF 0.49, while revenue for the quarter reached CHF 415.00K, missing expectations by -74.06%.
Earnings released on 31 Mar 2023
EPS came in at -CHF 0.45, while revenue for the quarter reached CHF 3.05M, beating expectations by +90.63%.
Earnings released on 31 Dec 2022
EPS came in at -CHF 0.48 surpassing the estimated -CHF 0.60 by +19.40%, while revenue for the quarter reached CHF 2.70M, missing expectations by -40.09%.
Earnings released on 30 Sept 2022
EPS came in at -CHF 0.41 surpassing the estimated -CHF 0.60 by +31.71%, while revenue for the quarter reached CHF 2.36M, missing expectations by -26.13%.
Earnings released on 30 Jun 2022
EPS came in at -CHF 0.14 surpassing the estimated -CHF 0.60 by +76.81%, while revenue for the quarter reached CHF 11.76M, missing expectations by -1.20%.
Earnings released on 31 Mar 2022
EPS came in at CHF 4.62 surpassing the estimated -CHF 0.60 by +870.00%, while revenue for the quarter reached CHF 172.78M, missing expectations by -1.27%.
Dividend declared on 15 Mar 2022
A dividend of CHF 0.29 per share was announced, adjusted to CHF 0.29.
Earnings released on 31 Dec 2021
EPS came in at -CHF 0.55, while revenue for the quarter reached CHF 1.80M.
Earnings released on 30 Sept 2021
EPS came in at -CHF 0.38 surpassing the estimated -CHF 0.57 by +33.10%, while revenue for the quarter reached CHF 3.53M, missing expectations by -74.94%.
Earnings released on 30 Jun 2021
EPS came in at -CHF 0.56, while revenue for the quarter reached CHF 3.44M.
Earnings released on 31 Mar 2021
EPS came in at -CHF 0.57, while revenue for the quarter reached CHF 977.00K.
Earnings released on 31 Dec 2020
EPS came in at -CHF 0.74, while revenue for the quarter reached CHF 1.55M.
Earnings released on 30 Sept 2020
EPS came in at -CHF 0.60, while revenue for the quarter reached CHF 283.00K.
0QXX.L Stock Performance
Access detailed 0QXX.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.